Needham & Company
-
Neogenomics (NEO) PT Lowered to $19 at Needham & Company
-
Neogenomics (NEO) PT Lowered to $29 at Needham & Company
-
Neogenomics (NEO) PT Lowered to $41 at Needham & Company
-
Neogenomics (NEO) PT Lowered to $48 at Needham & Company, Following Earnings
-
Guardant Health (GH) Sell-Off Makes Neogenomics (NEO) Deal Less Likely - Needham & Company
-
NeoGenomics to Participate in the 20th Annual Needham Virtual Healthcare Conference
-
Needham & Company Assumes Neogenomics (NEO) at Buy
-
NeoGenomics (NEO) Prices 4.081M Common Share Offering at $49/Sh; Announces Convertible Senior Notes Offering
-
NeoGenomics Announces Pricing of Public Offerings of Common Stock and Convertible Senior Notes
-
Neogenomics (NEO) Launches COVID-19 Testing, PT Raised to $39 as at Needham
-
NeoGenomics (NEO) Prices 4.4M Share Common Offering at $28.50/Sh; Prices Convertible Senior Notes
-
NeoGenomics Announces Pricing of Public Offerings of Common Stock and Convertible Senior Notes
-
Neogenomics (NEO) PT Raised to $29 at Needham & Company
-
Neogenomics (NEO) PT Raised to $27 at Needham & Company
-
NeoGenomics (NEO) Prices 7M Share Common Offering at $21.25/Sh
-
NeoGenomics Announces Pricing on Public Offering of Common Stock
-
NeoGenomics (NEO) to Offer $150M in Common Stock
-
NeoGenomics Announces Proposed Public Offering of Common Stock
-
NeoGenomics to Present at 18th Annual Needham & Company Health Care Conference
-
NeoGenomics (NEO) CEO Meeting Takeaways, PT To $22 At Needham
-
NeoGenomics (NEO) Model Update And PT Raise To $19 At Needham
-
Needham & Company Starts Neogenomics (NEO) at Buy